Takeda Pharmaceutical has signed licensing agreements with both Cipla and Sun Pharmaceutical to commercialize the gastrointestinal drug Vonoprazan in India. Cipla and Sun Pharma will market the drug under the brand name 'Voltapraz' in dosages of 10 mg and 20 mg. The agreements are non-exclusive, allowing both companies to distribute the drug in the Indian market. The announcement was made through an exchange filing.
